Catalogo dei prodotti della ricerca
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishIntroduction: To evaluate the safety profile characteristics of abiraterone acetate (AA) in the treatment of metastatic prostate cancer (mPCa). Areas covered: In this literature review the authors evaluate safety data from phase III trials investigating the combination of abiraterone acetate plus prednisone (AAP) in patients with metastatic prostate cancer. In particular, the aim was to clarify its toxicity profile, long-term exposure impact, and the correlation with general health-related quality of life (HRQoL). Expert opinion: Based on the studies reviewed, it appears that abiraterone acetate has favourable outcomes, is effective and well tolerated, mostly in asymptomatic or slightly symptomatic patients, and has recognised toxicity profile characteristics. Incidence of adverse events (AEs), such as mineralocorticoid- and corticosteroid-releated AEs, and hepatotoxicity is well known and widely described. Understanding the toxicity profile of AA could assist decision-making in clinical practice.
A drug safety evaluation of abiraterone acetate in the treatment of prostate cancer / Castellan, P.; Castellucci, R.; Marchioni, M.; De Nunzio, C.; Tema, G.; Primiceri, G.; Schips, L.; Cindolo, L.. - In: EXPERT OPINION ON DRUG SAFETY. - ISSN 1474-0338. - 18:9(2019), pp. 759-767. [10.1080/14740338.2019.1648428]
| Titolo: | A drug safety evaluation of abiraterone acetate in the treatment of prostate cancer | |
| Autori: | ||
| Data di pubblicazione: | 2019 | |
| Rivista: | ||
| Citazione: | A drug safety evaluation of abiraterone acetate in the treatment of prostate cancer / Castellan, P.; Castellucci, R.; Marchioni, M.; De Nunzio, C.; Tema, G.; Primiceri, G.; Schips, L.; Cindolo, L.. - In: EXPERT OPINION ON DRUG SAFETY. - ISSN 1474-0338. - 18:9(2019), pp. 759-767. [10.1080/14740338.2019.1648428] | |
| Handle: | http://hdl.handle.net/11573/1456546 | |
| Appartiene alla tipologia: | 01a Articolo in rivista |
File allegati a questo prodotto
| File | Note | Tipologia | Licenza | |
|---|---|---|---|---|
| Castellan_A drug safety_2019.pdf | Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione) | Tutti i diritti riservati (All rights reserved) | Open Access Visualizza/Apri |
http://hdl.handle.net/11573/1456546
Copyright © 2022